# A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

> **NCT00864253** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 529 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** ABI-007
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT00864253
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-23
- **Primary completion:** 2012-06-01
- **Final completion:** 2014-02-12
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2019-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00864253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00864253, "A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00864253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*